Related Experiment Video
Updated: Sep 28, 2025
Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors
Published on: March 1, 2020
CD133(+)HIF-1α(-) Expression After Chemoradiotherapy Predicts Poor Prognosis in Rectal Cancer
Yuichi Tachikawa1, Kazushige Kawai2, Kosuke Ozaki2
1Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan tachikawa35tsms@gmail.com.
Background/Aim:
CD133 and hypoxia-inducible factor 1α (HIF-1α) have been reported to be affected by chemoradiotherapy (CRT), but the combinatorial assessment of these markers for prognosis after CRT has not been fully investigated. Therefore, we aimed to predict recurrence and prognosis in patients with rectal cancer by assessing changes in the expression of both CD133 and HIF-1α after CRT.
Materials And Methods:
CD133 and HIF-1α expression was evaluated by immunohistochemistry in surgical specimens from 243 patients with advanced low rectal cancer who received CRT followed by curative resection.
Results:
The positivity rate of CD133 expression showed increase with increased HIF-1α expression. The combination of these two markers showed that the CD133(+)HIF-1α(-) group exhibited a markedly shorter relapse-free survival (p=0.007), higher liver recurrence (p=0.004), and higher local recurrence (p=0.006).
Conclusion:
CD133(+)HIF-1α(-) expression after CRT is a promising marker to predict recurrence in rectal cancer.
